Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739404 | 1.00 | ALDH1A1 (0.59) | ALDH1A1HSD17B10GPR35CYP19A1HIF1A | |
| SCHEMBL1424440 | 0.89 | ALDH1A1 (0.67) | ALDH1A1HSD17B10GPR35CYP19A1HIF1A | |
| SCHEMBL239666 | 0.84 | CYP19A1 (0.52) | ALDH1A1HSD17B10GPR35CYP19A1HIF1A | |
| SCHEMBL5872597 | 0.83 | ALDH1A1 (0.72) | ALDH1A1HSD17B10GPR35CYP19A1HIF1A | |
| SCHEMBL9693778 | 0.82 | GPR35 (0.61) | ALDH1A1HSD17B10GPR35CYP19A1HIF1A | |
| SCHEMBL8643676 | 0.80 | ALDH1A1 (0.60) | ALDH1A1HSD17B10GPR35CYP19A1HIF1A | |
| SCHEMBL6383570 | 0.80 | GPR35 (0.65) | ALDH1A1HSD17B10GPR35HIF1AKMT2A | |
| SCHEMBL31226497 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HSD17B10GPR35CYP19A1PDE7A | |
| SCHEMBL14744561 | 0.80 | ALDH1A1 (0.74) | ALDH1A1HSD17B10GPR35CYP19A1HIF1A | |
| SCHEMBL28515247 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HSD17B10GPR35CYP19A1PDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0667337-B1 | Method for preparing fluoroanilines | CLARIANT GMBH (DE) | 1998-01-21 | — | — | EP | claimed |
| US-5498794-A | Process for preparing fluoroanilines | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-03-12 | — | — | US | claimed |
| JP-62039549-A | — | — | None | — | — | JP | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| WO-2025235686-A1 | FLUOROCAMPTOTHECIN COMPOUNDS, CONJUGATES, AND METHODS THEREOF | Aarvik Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4619407-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | Curadev Pharma Ltd (GB) | 2025-09-24 | — | — | EP | disclosed |
| US-20250282794-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | CURADEV PHARMA LTD (GB) | 2025-09-11 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0667337-B1 | Method for preparing fluoroanilines | CLARIANT GMBH (DE) | 1998-01-21 | — | — | EP | disclosed |
| US-5498794-A | Process for preparing fluoroanilines | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-03-12 | — | — | US | disclosed |
| US-5349098-A | Process for producing chlorofluorobenzenes | ASAHI GLASS COMPANY LTD. (JP) | 1994-09-20 | — | — | US | disclosed |
| US-5208394-A | Process for producing chlorofluorobenzenes | ASAHI GLASS COMPANY LTD. (JP) | 1993-05-04 | — | — | US | disclosed |
| EP-0355719-A1 | Process for producing chlorofluorobenzenes | ASAHI GLASS COMPANY LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
| JP-S6239549-A | PRODUCTION OF 3,4-DIFLUOROANILINE | SEIMI CHEM KK | 1987-02-20 | — | — | JP | disclosed |
| EP-0001825-B1 | METHOD OF PREPARING 2,4-DIFLUOROANILINE | MERCK & CO. INC. (US) | 1982-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282794-A1 | PYRIDONE AND PYRIMIDINONE INHIBITORS OF HEMATOPOIETIC PROGENITOR KINASE 1 | PDXK, PGK1, CMPK1 | ALDH1A1 1053/4885HSD17B10 1986/4885GPR35 3298/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | ALDH1A1 2283/4885HSD17B10 3353/4885GPR35 889/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | ALDH1A1 2283/4885HSD17B10 3353/4885GPR35 889/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | ALDH1A1 2446/4885HSD17B10 2600/4885GPR35 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.